GRANULES Granules India Q3 FY25 results (Oct–Dec 2024) and concall
Granules India reported a mixed Q3 FY25, with revenue slightly down year-on-year but showing strong sequential growth. Gross margins improved significantly year-on-year, though EBITDA margins were impacted by one-off remediation and air freight costs related to the USFDA's 'Official Action Indicated' (OAI) classification for its Gagillapur facility. The company is actively addressing the OAI with 90% of CAPAs completed and is confident in its long-term growth trajectory, driven by new product launches, capacity expansion at Genome Valley, and focus on therapeutic areas like CNS ADHD and Oncolo
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 568 | 842 |
| EBITDA | 103 | 168 |
| Net profit | 41 | 90 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
